SIGNIFICANCE OF INFLAMMATION MARKERS DETERMINED IN PREGNANT WOMEN WITH ANEMIC SYNDROME AND OBESITY

The purpose of the present study was to specify a role of inflammatory mediators in pathogenesis of various types of anemia in pregnant obese women. We determined IL-1, IL-6, TNFα, C-reactive protein and hepcidin concentrations in blood serum of pregnant women with obesity depending on the type of anemic syndrome, either iron-deficiency anemia, or anemia of chronic diseases. We showed that the content of IL-6 in blood of the obese women exceeds the value of this index in healthy pregnant women (p < 0.05), and it does not depend on the presence and type of anemic syndrome. We found that the C-reactive protein concentration in pregnant women with obesity is higher than reference values (p < 0.05). Moreover, the contents of C-reactive protein in blood serum of pregnant women with anemia of chronic diseases is significantly higher (p < 0.05) than in women with iron deficiency anemia. Hepcidin concentration in blood of pregnant women with obesity and anemia of chronic disease was a specific feature: its content was significantly higher than in healthy pregnant women (p < 0.05), or in pregnant women with anemia-free obesity (p < 0.05). Hepcidin levels also exceeded 2-fold its contents in serum from pregnant women with obesity and iron deficiency anemia (p < 0.05). We have found that only pregnant women with obesity and anemia of chronic diseases have shown a positive correlation between the concentrations of C-reactive protein and blood levels of hepcidin (r = 0.733, p < 0.05), or IL-6 (r = 0.679, p < 0.05).
The discussion concerns potential mechanisms of evolving anemia of chronic disease combined with subclinical inflammation in pregnant women with metabolic disorders. We conclude that a combination of obesity with gestational diabetes is a risk factor of anemia of chronic diseases in pregnant women. Development of an algorithm for differential diagnosis of iron deficiency anemia and anemia of chronic diseases in this cohort of patients is advisable for future studies in the area.

1. Litvinova L.S., Kirienkova E.V., Gazatova N.D., Zatolokin P.A., Vasilenko M.A., Aksenov N.N., Simbirtsev A.S. Features cytokine mononukleanyh ability of peripheral blood cells of patients with metabolic syndrome. Tsitokiny i vospalenie = Cytokines and Inflammation, 2013, Vol. 12, no. 3, pp. 56-60. (In Russ.)

2. [Prokhorenko T.S., Zima A.P., Saprina T.V., Musina N.N., Shakhmanova N.S., Novitsky V.V. Differential diagnosis of anemia in pregnant women. Byulleten sibirskoy meditsiny = Bulletin of Siberian Medicine, 2017, Vol. 16, no 1, pp. 140-151. (In Russ.)

3. Prokhorenko T.S., Zima A.P., Saprina T.V., Novitsky V.V., Todosenko N.M., Litvinova L.S. Cytokine profile in pregnant women with metabolic disorders. Meditsinskaya immunologiya = Medical Immunology (Russia), 2017, Vol. 19, no. 3, pp. 301-306. (In Russ.) doi: 10.15789/1563-0625-2017-3-301-306.

4. Repina M.A., Bobrov S.A. Anemic syndrome in pregnancy: pathogenesis questions, diagnosis and treatment. Zhurnal akusherstva i zhenskikh bolezney = Journal of Obstetrics and Women Diseases, 2010, no. 2, pp. 3-11. (In Russ.)

5. Coimbra S., Catarino C., Santos-Silva A. The role of adipocytes in the modulation of iron metabolism in obesity. Obes. Rev., 2013. Vol. 14, no. 10, pp. 771-779.

6. Dao M.C., Sen S., Iyer C., Klebenov D., Meydani S.N. Obesity during pregnancy and fetal iron status: Is hepcidin the link? J. Perinatol., 2013, no. 33, pp. 177-181.

7. Ellulu M.S., Patimah I., Khaza’ai H., Rahmat A., Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch. Med. Sci., 2017, Vol. 13, no. 4, pp. 851-863.

8. Flores-Quijano M.E., Montalvo-Velarde I., Vital-Reyes V.S., Rodriguez-Cruz M., Rendon-Macias M.E., Lopez-Alarcon M. Longitudinal analysis of the interaction between obesity and pregnancy on iron homeostasis: role of hepcidin. Arch. Med. Res., 2016, Vol. 47, no. 7, pp. 550-556.

9. Friis C.M., Paasche Roland M.C., Godang K., Ueland T., Tanbo T., Bollerslev J., Henriksen T. Adiposityrelated inflammation: effects of pregnancy. Obesity (Silver Spring), 2013, Vol. 21, no. 1, pp. 124-130.

10. Gabrielsen J.S., Gao Y., Simcox J.A., Huang J., Thorup D., Jones D., Cooksey R.C., Gabrielsen D., Adams T.D., Hunt S.C., Hopkins P.N., Cefalu W.T., McClain D.A. Adipocyte iron regulates adiponectin and insulin sensitivity. J. Clin. Invest., 2012, Vol. 122, no. 10, pp. 3529-3540.

11. Ganz T., Nemeth E. Hepcidin and iron homeostasis. Biochim. Biophys. Acta, 2012, Vol. 1823, no. 9, pp. 1434-1443.

12. Koenig M.D., Tussing-Humphreys L., Day J., Cadwell B., Nemeth E. Hepcidin and iron homeostasis during pregnancy. Nutrients, 2014, Vol. 6, no. 8, pp. 3062-3083.

13. Meli R., Mattace Raso G., Irace C., Simeoli R., Di Pascale A., Paciello O., Pagano T.B., Calignano A., Colonna A., Santamaria R. High fat diet induces liver steatosis and early dysregulation of iron metabolismin rats. PLoS ONE, 2013, Vol. 8, no. 6, e66570. doi: 10.1371/journal.pone.0066570.

14. Nairz M., Haschka D., Demetz E., Weiss G. Iron at the interface of immunity and infection. Front. Pharmacol., 2014, Vol. 5, p. 152.

15. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., Ganz T., Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 2004, Vol. 306, no. 5704, pp. 2090-2093.

16. Nemeth E., Ganz T. Anemia of inflammation. Hematol. Oncol. Clin. North. Am., 2014, Vol. 28, no. 4, pp. 671-781.

17. Vuppalanchi R., Troutt J.S., Konrad R.J., Ghabril M., Saxena R., Bell L.N., Kowdley K.V., Chalasani N. Serum hepcidin levels are associated with obesity but not liver disease. Obesity (Silver Spring), 2014, Vol. 22, no. 3, pp. 836-841.

18. Zembala-Szczerba M., Jaworowski A., Huras H., Babczyk D., Jach R. Low-grade metabolically-induced inflammation mediators interleukin-6, adiponectin, and TNF-a serum levels in obese pregnant patients in the perinatal period. Med. Sci. Monit. Basic. Res., 2017, Vol. 23, pp. 1-7.